[go: up one dir, main page]

TR200200985T2 - Pürin türevleri - Google Patents

Pürin türevleri

Info

Publication number
TR200200985T2
TR200200985T2 TR2002/00985T TR200200985T TR200200985T2 TR 200200985 T2 TR200200985 T2 TR 200200985T2 TR 2002/00985 T TR2002/00985 T TR 2002/00985T TR 200200985 T TR200200985 T TR 200200985T TR 200200985 T2 TR200200985 T2 TR 200200985T2
Authority
TR
Turkey
Prior art keywords
purine derivatives
compounds
preparation
adenosine
solvates
Prior art date
Application number
TR2002/00985T
Other languages
English (en)
Inventor
Marina Monaghan Sandra
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR200200985T2 publication Critical patent/TR200200985T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

Mevcut bulus formül (I)'e göre olan bilesikler ve bunlarin farmakolojik olarak kabul edilebilir tuzlari ve solvatlari, bunlarin hazirlanmasi için usuller, bunlarin hazirlanmasinda kullanilan ara ürünler ve bu tip bilesikleri içeren bilesimler ve bu tip bilesiklerin adenosin A2a reseptör olarak kullanimi ile ilgilidir.
TR2002/00985T 1999-10-14 2000-10-06 Pürin türevleri TR200200985T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924363.6A GB9924363D0 (en) 1999-10-14 1999-10-14 Purine derivatives

Publications (1)

Publication Number Publication Date
TR200200985T2 true TR200200985T2 (tr) 2002-10-21

Family

ID=10862760

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00985T TR200200985T2 (tr) 1999-10-14 2000-10-06 Pürin türevleri

Country Status (50)

Country Link
US (1) US6350735B1 (tr)
EP (1) EP1220863B1 (tr)
JP (1) JP3994007B2 (tr)
KR (1) KR20020037774A (tr)
CN (1) CN1151167C (tr)
AP (1) AP1442A (tr)
AR (1) AR023275A1 (tr)
AT (1) ATE238336T1 (tr)
AU (1) AU768308B2 (tr)
BG (1) BG106569A (tr)
BR (1) BR0011776A (tr)
CA (1) CA2387531C (tr)
CO (1) CO5251399A1 (tr)
CR (1) CR6584A (tr)
CZ (1) CZ20021223A3 (tr)
DE (1) DE60002356T2 (tr)
DK (1) DK1220863T3 (tr)
DZ (1) DZ3159A1 (tr)
EA (1) EA004655B1 (tr)
EC (1) ECSP003712A (tr)
EE (1) EE200200193A (tr)
ES (1) ES2193990T3 (tr)
GB (1) GB9924363D0 (tr)
GE (1) GEP20043269B (tr)
GT (1) GT200000172A (tr)
HK (1) HK1047110B (tr)
HN (1) HN2000000204A (tr)
HU (1) HUP0203483A2 (tr)
IL (1) IL146342A0 (tr)
IS (1) IS6165A (tr)
MA (1) MA26828A1 (tr)
MX (1) MXPA02003812A (tr)
MY (1) MY136242A (tr)
NO (1) NO20021692D0 (tr)
NZ (1) NZ515323A (tr)
OA (1) OA12059A (tr)
PA (1) PA8503501A1 (tr)
PE (1) PE20010755A1 (tr)
PL (1) PL354932A1 (tr)
PT (1) PT1220863E (tr)
SI (1) SI1220863T1 (tr)
SK (1) SK4842002A3 (tr)
SV (1) SV2002000198A (tr)
TN (1) TNSN00202A1 (tr)
TR (1) TR200200985T2 (tr)
UA (1) UA66945C2 (tr)
UY (1) UY26397A1 (tr)
WO (1) WO2001027130A1 (tr)
YU (1) YU88901A (tr)
ZA (1) ZA200202849B (tr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
BR0209986A (pt) * 2001-05-25 2004-04-06 Pfizer Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
DE60318192T2 (de) * 2002-04-10 2008-04-30 The University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
SG155182A1 (en) * 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1893593A1 (en) * 2005-06-15 2008-03-05 Pfizer Limited 3-phenylazetidine derivatives as dopamine agonists
CN100352823C (zh) * 2005-08-19 2007-12-05 浙江车头制药有限公司 一种腺嘌呤衍生物的制备方法
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
US12324807B2 (en) 2018-06-01 2025-06-10 Cornell University Combination therapy for PI3K-associated disease or disorder
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5536419A (en) * 1978-09-08 1980-03-14 Yamasa Shoyu Co Ltd 2-substituted adenosine derivative and its preparation
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU5879299A (en) * 1998-10-16 2000-05-08 Monaghan, Sandra Marina Adenine derivatives

Also Published As

Publication number Publication date
EA004655B1 (ru) 2004-06-24
IS6165A (is) 2001-11-16
GEP20043269B (en) 2004-06-25
PE20010755A1 (es) 2001-07-17
SV2002000198A (es) 2002-02-05
GB9924363D0 (en) 1999-12-15
IL146342A0 (en) 2002-07-25
YU88901A (sh) 2004-09-03
MA26828A1 (fr) 2004-12-20
OA12059A (en) 2006-05-03
HK1047110B (zh) 2005-03-04
UA66945C2 (uk) 2004-06-15
CN1151167C (zh) 2004-05-26
CZ20021223A3 (cs) 2003-05-14
NO20021692L (no) 2002-04-10
EP1220863A1 (en) 2002-07-10
CR6584A (es) 2004-01-14
SI1220863T1 (en) 2003-10-31
WO2001027130A1 (en) 2001-04-19
DZ3159A1 (fr) 2001-04-19
ECSP003712A (es) 2002-05-23
PA8503501A1 (es) 2002-02-21
KR20020037774A (ko) 2002-05-22
TNSN00202A1 (fr) 2005-11-10
BG106569A (en) 2002-12-29
CO5251399A1 (es) 2003-02-28
CA2387531C (en) 2006-12-05
GT200000172A (es) 2002-04-05
PT1220863E (pt) 2003-07-31
AR023275A1 (es) 2002-09-04
EE200200193A (et) 2003-06-16
AU7548800A (en) 2001-04-23
JP3994007B2 (ja) 2007-10-17
PL354932A1 (en) 2004-03-22
ATE238336T1 (de) 2003-05-15
EP1220863B1 (en) 2003-04-23
AP1442A (en) 2005-06-29
CN1358192A (zh) 2002-07-10
JP2003511459A (ja) 2003-03-25
SK4842002A3 (en) 2003-06-03
DE60002356T2 (de) 2004-02-19
HK1047110A1 (en) 2003-02-07
MY136242A (en) 2008-08-29
ES2193990T3 (es) 2003-11-16
DK1220863T3 (da) 2003-08-11
MXPA02003812A (es) 2002-09-30
US6350735B1 (en) 2002-02-26
NO20021692D0 (no) 2002-04-10
CA2387531A1 (en) 2001-04-19
NZ515323A (en) 2003-10-31
BR0011776A (pt) 2002-03-12
UY26397A1 (es) 2001-05-31
AU768308B2 (en) 2003-12-04
DE60002356D1 (de) 2003-05-28
AP2002002478A0 (en) 2002-06-30
EA200101107A1 (ru) 2002-10-31
HUP0203483A2 (hu) 2003-02-28
ZA200202849B (en) 2003-06-25
HN2000000204A (es) 2001-06-21

Similar Documents

Publication Publication Date Title
TR200200985T2 (tr) Pürin türevleri
TR200201001T2 (tr) Pürin türevleri
TR200401622T4 (tr) Pürin türevleri
EA200101203A1 (ru) Производные пурина
EA200200770A1 (ru) Производные пурина
CA2422374A1 (en) Purine derivatives
ATE331726T1 (de) Adenine-derivate
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
TR199800436A2 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
ATE307132T1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
BR0011856A (pt) Agonistas de receptor a2a de n-pirazol
NO20035524D0 (no) 4'-substituerte nukleosider
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AU2003215680A1 (en) New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives
TR200102501T2 (tr) Antiviral nükleozid analoglar.
TR199901380A2 (tr) Di-ya da triazo-spiro[4,5] dekan türevleri